HOME - 2nd Health Equity and Outcomes Summit

On-Demand Content | Virtual Event

If you have any questions about your purchase, please contact javiera@momentumevents.com with any issues you are experiencing

Health Equity has become a growing issue of focus for pharmaceutical companies in recent years. With global events, including the COVID-19 pandemic; health inequities, especially within marginalized and underserved communities have been put under a microscope.

With a great push from both governmental and public entities, pharmaceutical companies have the daunting task of finding ways to be impactful socially through market access, health equity, and SDoH research, innovation, and development while still creating commercial value. While these companies have been making strides towards removing many barriers to health equity, there is still a long way to go.

This event will showcase how pharma companies collaborating with external and internal partners can truly close the gap on health equity and social disparities while also ensuring commercial success. Understanding that you can make an impact and still create an increase in fiscal achievement are key takeaways that can not be overlooked and should be at the forefront of your business models.

SPEAKER HIGHLIGHTS

VIEW ALL SPEAKERS

Top Reasons to Purchase

Bridge the gap between the commercial and social side of pharma and discern how industry leaders are blending fiscal success with social change
Address the need for diversity and inclusion across clinical trials, while building trust and removing alienation from those with severe and long-standing health inequities and allow access to new revenue streams
Integrate innovative and impactful equity, diversity and inclusion Initiatives into your commercial business model that leads to more diverse channels of fiscal success
Gain knowledge of how to create and sustain Market Access for at risk patients, especially those with significant health inequities that also addresses payer satisfaction
Develop strategies to keep diverse and qualified staffing for clinical trials that create and environment of trust and understanding for marginalized patients and reduces staffing burnout, especially within underserved and marginalized communities
Understand the importance of increasing positive patient outcomes across all therapeutic and care related areas, thusly removing barriers to health and wellness as well as develop recurring returns and earnings in new commercial spaces

Who Should Purchase

Pharmaceutical, Biotechnology, medical device, payers, and health system professionals whose responsibilities include:

Primary Market:

Health Equity
Diversity
Payer and Market Access
Payer Marketing
Marketing (likely at VP level)
Heads of Therapeutic Categories (typically the larger disease states such as Oncology, CV, Immunology, Respiratory etc)
DE&I
Market Access
ESG (Environment, Social, and Government Policy)
Commercial Strategy
Multicultural Marketing
Population Health Marketing
Digital Health
Patient Engagement
Patient Centricity

Patient Solutions
Patient Advocacy
Health Systems Liaisons
Medical Director
Care Coordination
Engagement Lead, Clinical Trials
Strategic Partnerships
Global Partnerships
New Partnerships
HEOR (Health Economics and Outcomes Research)
CSR
Media Relations

Secondary Market:

Digital Agencies (can be part of patient support services or diversity strategy, or trial recruitment assistance)
PR Firms
Data Aggregators
Clinical Trial Recruitment/Engagement vendors